Sugi Predict

Sugi Predict / Compounds / SCHEMBL20456344

SCHEMBL20456344

SCHEMBL20456344

CC(C)(C)OC(=O)N1C(=O)CCC12CC2

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ CHRM3 P20309 1/20 0.37
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ BUB1 O43683 1/20 0.35
▸ DDB1 Q16531 3/20 0.35
▸ CRBN Q96SW2 3/20 0.35
▸ ELANE P08246 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ GRIN2B Q13224 1/20 0.32
▸ GRIN2C Q14957 1/20 0.32
▸ KDM1A O60341 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ NR1H2 P55055 1/20 0.32
▸ CTSK P43235 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6921819 0.93 CHRM2 (0.35) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL9948965 0.89 USP2 (0.44) USP2SMN1; SMN2DDB1CRBNESR2
SCHEMBL6922466 0.88 CHRM2 (0.32) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL29348855 0.87 USP2 (0.38) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL33525787 0.87 CHRM2 (0.35) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL6921988 0.87 CRBN (0.35) CHRM2CHRM1CHRM3BUB1DDB1
SCHEMBL25783891 0.83 BRD4 (0.38) CHRM2CHRM1CHRM3SMN1; SMN2DDB1
SCHEMBL3658980 0.83 BUB1 (0.38) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL25783982 0.82 CHRM2 (0.37) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL9948963 0.81 USP2 (0.42) USP2SMN1; SMN2DDB1CRBNKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688156-A1 LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS Janssen Pharmaceutica NV (BE) 2026-02-11 — — EP disclosed
US-20250346602-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF DICE ALPHA INC (US) 2025-11-13 — — US disclosed
US-20250243187-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-07-31 — — US disclosed
EP-4551569-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
EP-4525987-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF Dice Alpha, Inc. (US) 2025-03-26 — — EP disclosed
WO-2024201322-A1 LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 — — WO disclosed
EP-3577118-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION GILEAD SCIENCES INC (US) 2024-09-04 — — EP disclosed
US-12065428-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-08-20 — — US disclosed
CN-118159548-A Antiviral compounds 安力高医药股份有限公司 2024-06-07 — — CN disclosed
EP-4366831-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2024-05-15 — — EP disclosed
US-20230140238-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-05-04 — — US disclosed
EP-4165037-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS Aligos Therapeutics, Inc. (US) 2023-04-19 — — EP disclosed
WO-2023043816-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS ALIGOS THERAPEUTICS, INC. (US) 2023-03-23 — — WO disclosed
US-20230093249-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-03-23 — — US disclosed
WO-2023283256-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2023-01-12 — — WO disclosed
US-20220009903-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-01-13 — — US disclosed
WO-2021252491-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS ALIGOS THERAPEUTICS, INC. (US) 2021-12-16 — — WO disclosed
US-10442804-B2 Compounds for the treatment of hepatitis B virus infection GILEAD SCIENCES, INC. (US) 2019-10-15 — — US disclosed
US-20180251460-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION GILEAD SCIENCES, INC. 2018-09-06 — — US disclosed
WO-2018144605-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2018-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251460-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION HAVCR2, PYGL, OAT CHRM2 3533/4885CHRM1 3929/4885CHRM3 2427/4885
US-20250243187-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 CHRM2 4868/4885CHRM1 4859/4885CHRM3 4863/4885
US-12065428-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 CHRM2 4868/4885CHRM1 4859/4885CHRM3 4863/4885
US-20250346602-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF IL17A, IL15, IL18 CHRM2 4776/4885CHRM1 4592/4885CHRM3 4851/4885
US-20230140238-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 CHRM2 4868/4885CHRM1 4859/4885CHRM3 4863/4885
US-10442804-B2 Compounds for the treatment of hepatitis B virus infection HAVCR2, PYGL, OAT CHRM2 3533/4885CHRM1 3929/4885CHRM3 2427/4885
US-20230093249-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 CHRM2 4868/4885CHRM1 4859/4885CHRM3 4863/4885
US-20220009903-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 CHRM2 4868/4885CHRM1 4859/4885CHRM3 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.